Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma | Zendy

Jawaher Ansari | Zendy; Syed A. Hussain | Zendy; Glaholm | Zendy; Asif Ansari | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Author(s) -

Jawaher Ansari,

Syed A. Hussain,

Glaholm,

Asif Ansari

Publication year - 2013

Publication title -

biologics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.948

H-Index - 38

eISSN - 1177-5491

pISSN - 1177-5475

DOI - 10.2147/btt.s25862

Subject(s) - axitinib , renal cell carcinoma , critical appraisal , medicine , oncology , pathology , alternative medicine , sunitinib

A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research